- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00801307
Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease
A Single Site,Exploratory,Phase I/II,Randomised Trial Comparing the Effect of He/O2 Mixtures(He/O2 78:22 and He/O2 65:35) to Medical Air on Pulmonary Function in Moderate/Severe Asthma and COPD Patients and Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Two types of measurements will be performed with each of the three evaluated gases:
- pulmonary function measurements at rest to establish the resistance to airflow in a reproducible way, including the measurements of Inspiratory Capacity (IC), Forced Expiratory Volume in 1 second (FEV1), Forced Expiratory Flows (FEF) at different lung volumes (25 to 75% of the vital capacity), and Forced Vital Capacity (FVC),
- Tidal Volume (TV) measured at rest and during light cycling exercise. The results of this study should be useful to evaluate the extent of influence on gas concentration, since none of the previous trials have been performed with He/O2 65:35, as well as the extent of influence on the lung disease, since none of the previous trials have been performed with asthmatic patients at various disease stages.
The working hypothesis is that when using He/O2 mixtures 78:22 and 65:35, the flow resistance decreases as compared to medical air because low density helium replaces nitrogen, thus resulting in a lower workload of breathing for asthmatic and COPD patients. For patients with reduced pulmonary function, this difference might result in greater Inspiratory Capacity.
That is why Inspiratory Capacity will be measured as primary efficacy criterion, but also Tidal Volume and other pulmonary function parameters on 3 types of subjects/patients :
- healthy volunteers,
- patients with moderate and severe persistent asthma,
- patients with moderate and severe COPD.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Gauting
-
Robert-Koch-Allee 2, Gauting, Germany, 82131
- Inamed Research GmbH & Co. KG
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All subjects/patients:
- Willing and able to complete the requirements of this study including the signature of the written informed consent,
- Able to complete the study in 5 working days or less,
- Able to perform pulmonary function tests
Healthy volunteers:
- Never smoker or subject who stopped smoking at least 6 months before selection (strictly less than 10 pack-years),
- Having pulmonary function tests within the normal range(according to predicted values for age, sex and height as referenced in ATS/ERS 1993 standards)
Patients with moderate/severe persistent asthma:
- Documented clinical diagnosis of moderate or severe persistent asthma (according to GINA 2006 guidelines),
- Stable asthma in the 4 weeks prior to selection as evidenced by no change in asthma medication, no treatment for asthma in an emergency,acute care setting and no admission to hospital for acute asthma
Patients with moderate / severe COPD:
- Aged ≥ 45 and £ 80 years old,
- Documented clinical diagnosis of moderate or severe COPD(according to GOLD 2006 guidelines),
- With a smoking history of 10 pack-years or more,
- Stable COPD in the 4 weeks prior to selection as evidenced by no change in COPD medication, no treatment for COPD in an emergency, acute care setting and no admission to hospital for COPD exacerbation
Exclusion Criteria:
- Obese subject/patient having a Body Mass Index (BMI) > 35,
- Past or present respiratory disease including being free from the common cold and rhinitis for at least 4 weeks before selection except asthma for asthmatic patients and COPD for COPD patients,
- Daily need for 12 hours or more of long term oxygen therapy,
- Pregnant or lactating woman,
- Lack of efficient contraception according to CPMP/ICH 286/95 note 31,
- Any contra-indication to perform pulmonary function tests or light cycling exercise,
- Clinically significant or uncontrolled pathologic conditions which may interfere with the study procedures,
- Drug abuse or psychic disorders resulting in an inability to fully understand the requirements of the study,
- Legal status which prohibits informed consent,
- Participation in any interventional clinical trial within 30 days prior to selection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
He/O2 78:22
|
According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
Other Names:
|
Experimental: 2
He/O2 65:35
|
According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
Other Names:
|
Active Comparator: 3
Medical Air
|
According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Inspiratory Capacity measured by spirometry at rest while breathing each He/O2 mixture compared to its measurement on medical air
Time Frame: 30 mn
|
30 mn
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Inspiratory Capacity measured by ergospirometry while breathing Pulmonary function parameters at rest, i.e., FEV1, FVC, FEF25-75, PEF and ERV while breathing each He/O2 mixture compared to medical air,
Time Frame: 20 Mn
|
20 Mn
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas Meyer, Dr. med., Inamed Research GmbH & Co. KG
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALMED-07-C2-012
- 2007-004158-10 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on spirometer
-
Mayo ClinicEnrolling by invitationPulmonary EmbolismUnited States
-
Lahey ClinicCompletedPneumonia | Pulmonary Atelectasis | Obesity, Morbid | Complications of Bariatric ProceduresUnited States
-
Carmel Medical CenterCompletedSigns and Symptoms, Respiratory | Allergy | Bronchial AsthmaIsrael
-
Carmel Medical CenterCompletedSigns and Symptoms, Respiratory | Allergy | Bronchial AsthmaIsrael
-
Carmel Medical CenterCompletedSigns and Symptoms, Respiratory | Allergy | Bronchial AsthmaIsrael
-
Universidad Católica de ÁvilaCompletedObstructive Pulmonary DiseaseSpain
-
University of MichiganCompletedCystic FibrosisUnited States
-
National Taipei University of Nursing and Health...Tri-Service General HospitalNot yet recruitingHypertension | Diabetes | Long COVID | Cardiac Disease | COVID-19 Pandemic
-
University of NottinghamAstraZenecaRecruitingChronic Obstructive Pulmonary Disease | AsthmaUnited Kingdom
-
Diskapi Yildirim Beyazit Education and Research...CompletedCoronavirus Infection | Pneumonia, Viral | Covid19 | Respiratory Function LossTurkey